Sabo JP, Lamson MJ, Leitz G, Yong CL and MacGregor TR Pharmacokinetics of Nevirapine and Lamivudine in Patients with HIV-1 Infection AAPS PharmSci 2000; 2 (1) article 1 (https://www.pharmsci.org/scientificjournals/pharmsci/journal/1.html).

Figures and Tables

Figure 1.Frequency distribution of the elapsed time after dosing for 177 samples; the time values represent the midpoints of 1-hour intervals.

Table 1.

Table 2.

Figure 2.Observed concentrations of nevirapine (circles) and steady-state concentration profile.

Table 3.

Figure 3.Post hoc estimates of lamivudine's (3TC) apparent clearance and half-life. The bottom and top of each box represent the 25th and 75th percentiles, with the median drawn at the center of the notched area. The vertical lines extend to 1.5 interquartile ranges. Values more extreme are outliers and are marked by closed circles. The notched area above and below the median mark the confidence intervals.

Figure 4.Lamivudine (3TC) serum concentrations in the absence (blue line, closed circles) and presence (red line, open circles) of cotrimoxazole (TMP/SMX).